MTD Second Quarter Earnings Beat Estimates on China-Led Sales Growth

MTD Navigates a More Favorable Regional Backdrop

On a local-currency basis, MTD's sales increased 3% in the Americas, 4% in Europe and 10% in Asia/Rest of World in the quarter. Excluding acquisitions and one-time tariff refunds to customers, organic local-currency sales increased 4%, including 1% growth in the Americas and 9% growth in Asia/Rest of World.

By geography, Americas sales declined to $402 million from $414 million, accounting for 39% of total revenues. Europe sales increased to $294 million from $274 million and represented 29% of revenues, while Asia/Rest of World sales rose to $331 million from $295 million, contributing 32% of total revenues.

Mettler-Toledo Sees Strength Across Businesses

Laboratory sales increased to $553 million from $538 million in the prior-year quarter. Industrial sales improved to $418 million from $395 million, while Food Retail revenues increased to $57 million from $51 million.

On an organic local-currency basis, Laboratory sales increased 4%, Industrial sales rose 3%, including 4% growth in Core Industrial and 1% growth in Product Inspection, while Food Retail sales climbed 11%. Service revenues increased 9%, or 7% organically.

Management noted that China delivered 9% growth, supported by Industrial demand, while emerging markets outside China also posted high-single-digit growth. Improved conditions in biopharma, automation, semiconductor, batteries and food manufacturing markets also aided performance.

MTD Expands Margins Despite Higher Expenses

Adjusted gross profit increased to $625.7 million from $579.9 million. Adjusted gross margin expanded 30 basis points year over year to 59.3%, benefiting from pricing, lower tariff rates, productivity initiatives and volume growth, partly offset by higher transportation costs.

Research and development expenses increased to $53 million from $49.3 million. Selling, general and administrative expenses rose to $263.3 million from $247.3 million.

Adjusted operating profit increased 9% year over year to $309.3 million. Adjusted operating margin expanded 50 basis points to 29.3%. Reported diluted earnings per share were $11.55 compared with $9.76 in the prior-year quarter.

Mettler-Toledo Balance Sheet Remains Solid

As of June 30, 2026, cash and cash equivalents were $51.4 million compared with $60.5 million as of March 31, 2026. Long-term debt declined sequentially to $2.04 billion from $2.16 billion.

Year-to-date adjusted free cash flow totaled $367 million. Management noted that free cash flow was affected by the timing of tax payments, which were $55 million higher than the prior year.

The company also increased its planned share repurchases for 2026 to $875 million from the annualized first-half pace of $825 million.

MTD's Q3 & FY26 Guidance

Management cautioned that market conditions remain uncertain and could change quickly, but guided for third-quarter 2026 local-currency sales growth of approximately 4%. Adjusted earnings for the third quarter are forecast to be in the range of $12-$12.15 per share, implying 8-9% growth year over year.

For 2026, MTD raised its local-currency sales growth outlook to approximately 4-5% from the prior view of approximately 4%, and raised adjusted earnings guidance to $47.15-$47.50 per share, representing growth of 10-11%, from the prior outlook of $46.30-$46.95.

Zacks Rank & Other Stocks to Consider

MTD currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the broader Zacks Medical sector are Progyny PGNY, Centene CNC and GETINGE GNGBY, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Shares of Progyny have surged 21.2% year to date. The Zacks Consensus Estimate for Progyny’s 2026 earnings is pegged at $2.04 per share, up by 3.55% over the past 30 days, indicating an increase of 7.94% year over year.

Shares of Centene have jumped 51.2% year to date. The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $4.71 per share, up 36.13% over the past 30 days, indicating a rise of 126.44% year over year.

GETINGE shares have appreciated 5.2% year to date. The Zacks Consensus Estimate for GETINGE’s 2026 earnings is pegged at $1.38 per share, up by 9.52% over the past 30 days, indicating an increase of 20% year over year.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research